Skip to main content
Premium Trial:

Request an Annual Quote

Keeping Up With Flatley

Illumina CEO Jay Flatley tells Xconomy's Luke Timmerman that for a long time there was no innovation in the industry until the advent of next-gen sequencing which caused "huge amount of money" to be invested in the space. Currently, Flatley considers Life Technologies to be Illumina's primary competitor, but says his company is "way ahead" in terms of market share. However, there are also a few upstarts, such as Complete Genomics, who are encroaching on part of the market Illumina considers to be its own. As for when the $1,000 genome will materialize, Flatley says that "if you count bioinformatics, if you count sample prep, if you count data storage in the number, if you count it all, then it's somewhere in the three to five-year timeframe. ... The sequencing will get there faster than that."

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.